Dexmedetomidine load + Ketamine load + Midazolam load + Fentanyl load + Dexmedetomidine maintenance + Ketamine maintenance + Midazolam demand + Fentanyl demand + Benadryl demand
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Sedation
Conditions
Sedation
Trial Timeline
Jun 1, 2010 → May 1, 2012
NCT ID
NCT01158820About Dexmedetomidine load + Ketamine load + Midazolam load + Fentanyl load + Dexmedetomidine maintenance + Ketamine maintenance + Midazolam demand + Fentanyl demand + Benadryl demand
Dexmedetomidine load + Ketamine load + Midazolam load + Fentanyl load + Dexmedetomidine maintenance + Ketamine maintenance + Midazolam demand + Fentanyl demand + Benadryl demand is a approved stage product being developed by Pfizer for Sedation. The current trial status is completed. This product is registered under clinical trial identifier NCT01158820. Target conditions include Sedation.
What happened to similar drugs?
7 of 20 similar drugs in Sedation were approved
Approved (7) Terminated (2) Active (13)
🔄Intralipid + ICI35,868 (Diprivan) + ICI35,868 (Diprivan) + EES0000645/A (SDS)Johnson & JohnsonPhase 3
🔄Remimazolam Tosilate + Propofol Medium and Long Chain Fat Emulsion InjectionJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01158820 | Approved | Completed |
Competing Products
20 competing products in Sedation